Charite University Hospital Berlin
BerlinProtonen – Proton therapy at Charité (253171)
Specialized in: proton therapy
The BerlinProtonen under the direction of Dr. rer. nat. Andrea Denker specializes in in the use of proton therapy in the treatment of eye tumors. Since 1998, proton therapy has been considered as a successful and highly effective method of treating intraocular tumors. The systematic cooperation of medical physicists, radiation therapists and ophthalmologists has greatly improved the accuracy of the therapy, which is a benefit for the patients. Today, the innovative therapy of BerlinProtonen can slow down the tumor growth and preserve the useful visual function of the affected eye in 95% of patients, even in case of multiple large tumors.
The decisive advantage of proton irradiation is its release of energy into the effected tissues (Bragg peak), which allows an accurate irradiation of the tumor and protection of the immediately adjacent organs. The BerlinProtonen can provide a device for emitting a proton beam with an energy output of 68 MeV that can penetrate into the body to a depth of about 30 mm. This energy is ideal for treating tumors inside the eye. Malignant melanomas of the uvea should be irradiated first. These can be divided into choroidal melanomas or ciliary body melanomas and iris melanomas. In addition, proton therapy can be used to treat other tumors, such as conjunctival melanoma, hemangioma and retinoblastoma.
The terminal proton therapy for large tumors should be followed by the subsequent treatment to improve eye function and observation.
- Berlin, Germany